Thank you, Rob, and good morning, everyone. NAV increased $252 million from the first quarter, driven primarily by positive performance in CVI, offset by decreases in Viskase and Auto Service. CVI share price increased by 38%, which when combined with additional share purchases of $32 million led to an increase of $561 million from the first quarter. Crack spreads have improved, especially diesel cracks, and we have no more planned turnarounds in 2025 and 2026. This enhanced cash flow profile has led to CVI recently paying down $90 million of its previously issued term loan. Regarding RINs, we remain hopeful that the new administration may lead to the resolution of our outstanding litigation regarding small refinery exemptions, which has the potential to remove the $548 million liability that was recorded as of the second quarter of 2025 and potentially provide clarity to future years. We also announced that CVI's CEO, Dave Lamp, would be retiring as of year-end. His replacement, Mark Pytosh, is an internal promotion who has been the CEO of the fertilizer business and also led CVI's midstream efforts for the past few years. The investment funds ended down approximately 0.5% for the quarter, primarily driven by gains in our consumer cyclical sector, offset by our broad market and refining hedges. Excluding the refining hedges, fund performance would have been a positive return of 2%. Our Auto Service division remains a turnaround story. We are encouraged by the change in top line revenue. After seeing first quarter Auto Service revenue down 5% year-over-year, we saw revenue improve to 1% growth in both May and June, and it will accelerate further in July. In our Pharma segment, we have approved the initiation of VIVUS' pivotal trial for the pulmonary arterial hypertension or PAH asset, VI-0106. In short, this drug is meant to serve patients with advanced PAH who struggle to breathe, provide oxygen to the blood and maintain mobility and/or quality of life given the restriction of blood flow in their arteries leaving the heart to the lungs. Currently, there are multiple alternative treatments in the market. The latest treatment is marketed under the name WINREVAIR. With any current PAH treatment, the patient may still require a lung transplant and/or heart transplant, which will not address the underlying cause of PAH. We believe our asset is unique and the FDA will evaluate the potential of this drug to be disease-modifying. The trial will enroll 300 patients and includes unique analyses and clinical end points. As the trial progresses, we will provide updates with the first one expected in approximately 12 to 18 months from now. We ended the quarter with $1.1 billion of cash and cash equivalents at the holding company, an additional $700 million of cash at the funds. So as Carl likes to say, we have a significant war chest to take advantage of opportunities as they arise. Lastly, the Board has maintained the quarterly distribution at $0.50 per depositary unit. Now turning to our Investment segment. Despite the market volatility, we see considerable value creation potential in our portfolio. At AEP, we see new management closing its ROE gap, improving regulatory outcomes, solidifying its balance sheet and benefiting from tremendous electricity load growth due to AI-driven data center demand. We think electric utilities, particularly AEP, which is operations in real data center hotspots of Texas, Indiana and Ohio are an excellent way to benefit in the picks and shovels of AI. At SWX, we see a gas utility that is closing its ROE gap to peers, seeing a push towards more favorable rate making in both Nevada and Arizona and seeing attractive investment opportunities through the potential expansion of its FERC regulated gas pipeline. During the second quarter, SWX was also able to execute on 2 sell-downs of Centuri, its Utility Services division, getting the companies closer to a full separation. We believe that Centuri should also see an attractive multiyear growth opportunity given continued investment in the electrical and gas grids needed to drive all of the infrastructure investment from data centers, electrification and reshoring. At Caesars, we have an excellent management team with tremendous owned real estate value and a growing digital business that is deploying its greater than 15% free cash flow yield to repurchase shares and repay debt. We think the digital business is really underappreciated. In fact, in the second quarter, the digital business grew revenue 24% and EBITDA 100%. In time, we would expect Caesars Digital business to be unlocked from its current structure the Caesars share price does not reflect the tremendous value of the business. The Funds ended the quarter approximately 2% net long. Adjusting for our refining hedges, the Fund was 23% net long. And now I will pass it on to Ted to cover our controlled businesses.